ARTICLE | Clinical News
FDA approves Orencia for psoriatic arthritis
July 13, 2017 2:27 AM UTC
FDA approved Orencia abatacept from Bristol-Myers Squibb Co. (NYSE:BMY) to treat psoriatic arthritis. The product is a CTLA-4 (CD152)-Ig fusion protein available in both IV and subcutaneous formulatio...
BCIQ Company Profiles